IGFBP7 and myeloid sarcoma: The diagnostic ability was further evaluated to distinguish SPMS from RRMS, as serum IGFBP7 had a higher AUC (0.747) than CSF IGFBP7 (AUC: 0.707) (Figure 7B), which indicates that serum IGFBP7 may be a more appropriate marker as MS phenotypes than CSF IGFBP7 in clinical practice.